Escipion Pedroza, MD
Endocrinology, Diabetes & Metabolism · Metairie, LANPI 1306807771
Payments from drug & device makers
Across 89 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$276
- Boehringer Ingelheim$154
- Xeris Pharmaceuticals, Inc.$131
- Medtronic$128
- Dexcom, Inc.$109
- AstraZeneca$102
- plus $755 from 21 others
What the payments were for
- Food & beverage$1,61197%
- Education$433%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 15 | $276 |
| Boehringer Ingelheim | 9 | $154 |
| Xeris Pharmaceuticals, Inc. | 7 | $131 |
| Medtronic(2 entities) | 7 | $128 |
| Dexcom, Inc. | 5 | $109 |
| AstraZeneca(2 entities) | 6 | $102 |
| AbbVie | 5 | $93 |
| IBSA Pharma Inc. | 4 | $81 |
| Bayer | 4 | $78 |
| Amgen(2 entities) | 3 | $57 |
| Astellas Pharma US Inc | 3 | $50 |
| Abbott | 2 | $48 |
| Mannkind Corporation | 1 | $43 |
| Ascendis Pharma Endocrinology Inc | 2 | $42 |
| Novo Nordisk | 2 | $34 |
| BETA Bionics, Inc. | 2 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Pfizer | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Qiagen, LLC | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$1,654 in reported general payments places this provider in the 35th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 182 | $226,335 |
| MounjaroTirzepatide | 153 | $178,135 |
| JardianceEmpagliflozin | 142 | $163,374 |
| JanuviaSitagliptin Phosphate | 89 | $104,542 |
| TradjentaLinagliptin | 67 | $73,425 |
| TrulicityDulaglutide | 64 | $71,777 |
| FarxigaDapagliflozin Propanediol | 64 | $69,051 |
| JanumetSitagliptin Phos/Metformin Hcl | 82 | $60,801 |
| EliquisApixaban | 29 | $38,901 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 202 | $37,885 |
| Humulin R U-500Insulin Regular, Human | 21 | $31,508 |
| InvokanaCanagliflozin | 31 | $29,014 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 12 | $20,530 |
| ProliaDenosumab | 11 | $19,173 |
| Novolog FlexpenInsulin Aspart | 66 | $16,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Humulin N, Humulin 70-30 | $276 | $269,641316 claims |
| Novo NordiskOzempic, Novolog, Levemir | $34 | $248,266227 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $154 | $242,070220 claims |
| MerckJanuvia, Janumet | $12 | $165,343171 claims |
| AstraZenecaFarxiga, Symbicort | $102 | $71,83676 claims |
| PfizerEliquis | $20 | $38,90129 claims |
| Johnson & JohnsonInvokana | $16 | $29,01431 claims |
| AmgenProlia | $57 | $19,17311 claims |
| AbbVieSynthroid | $93 | $13,475126 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $33 | $3,979532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Metairie
- Tuan Huy TranMetairie$2M
- Jonathan WiseMetairie$463K
- Julie TalaveraMetairie$49K
- Joseph MurrayMetairie$7K
- Miguel RiveraMetairie$7K
- Harold MillerHammond$1.1M
- Timothy GilbertBaton Rouge$985K
- Justin FontenotLafayette$905K
- Vivian FonsecaNew Orleans$700K
- Frank GreenwayBaton Rouge$669K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.